CSBR
Champions OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade D from latest DB weights. Momentum 31.5 / Value 60.8
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-21 · AMC.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
31
Value
61
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Earnings
2026-07-21 · AMC
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum31 · Δ7d -
Value61 · Δ7d -0.5
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
31
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
61
60% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+0.5
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 31.5 / Value 60.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$84.71M
Beta
0.36
Shares Out
13.89M
P/E (TTM)
40.3
P/S (TTM)
1.59
P/FCF (TTM)
16.52
Rev YoY
-2.8%
EPS YoY
-106.4%
Gross Margin
+43.4%
Op Margin
+3.7%
Net Debt
-$3.46M
Current Ratio
0.98
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology